Collegium Pharmaceutical Inc (COLL)

Currency in USD
37.74
+0.58(+1.56%)
Closed·
37.740.00(0.00%)
·
COLL Scorecard
Full Analysis
Management has been aggressively buying back shares
COLL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
37.1237.85
52 wk Range
23.2342.29
Key Statistics
Prev. Close
37.16
Open
37.38
Day's Range
37.12-37.85
52 wk Range
23.23-42.29
Volume
352.19K
Average Volume (3m)
316.7K
1-Year Change
7.03%
Book Value / Share
7.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
COLL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
44.20
Upside
+17.12%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Collegium Pharmaceutical Inc Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Employees
357

Collegium Pharmaceutical Inc Earnings Call Summary for Q1/2025

  • Net product revenues reached $177.8M, up 23% YoY; stock rose 0.85% to $27.27 in aftermarket trading
  • Jornay PM (ADHD medication) saw 24% prescription growth; BELBUCA revenue up 2% YoY to $51.7M
  • Cash position improved by $35M to $197.8M; Non-GAAP adjusted EBITDA up 3% YoY to $95.2M
  • 2025 guidance: net product revenues $735M-$750M (18% increase); Jornay PM expected to exceed $135M
  • CEO emphasized leadership in responsible pain management; plans to reduce operating expenses in H2 2025
Last Updated: 08/05/2025, 22:16
Read Full Transcript

Compare COLL to Peers and Sector

Metrics to compare
COLL
Peers
Sector
Relationship
P/E Ratio
32.8x−5.3x−0.6x
PEG Ratio
−0.580.000.00
Price/Book
5.1x0.7x2.6x
Price / LTM Sales
1.7x1.4x3.3x
Upside (Analyst Target)
19.2%94.7%40.2%
Fair Value Upside
Unlock15.7%5.1%Unlock

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 44.20
(+17.12% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
1.68 / 1.66
Revenue / Forecast
188.00M / 182.69M
EPS Revisions
Last 90 days

COLL Income Statement

People Also Watch

246.65
AVAV
-1.23%
150.27
KRYS
-0.04%
38.31
EXEL
-0.42%
36.87
HRMY
+0.99%
48.82
PTCT
+0.25%

FAQ

What Stock Exchange Does Collegium Pharmaceutical Trade On?

Collegium Pharmaceutical is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Collegium Pharmaceutical?

The stock symbol for Collegium Pharmaceutical is "COLL."

What Is the Collegium Pharmaceutical Market Cap?

As of today, Collegium Pharmaceutical market cap is 1.19B.

What Is Collegium Pharmaceutical's Earnings Per Share (TTM)?

The Collegium Pharmaceutical EPS (TTM) is 1.13.

When Is the Next Collegium Pharmaceutical Earnings Date?

Collegium Pharmaceutical will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is COLL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Collegium Pharmaceutical Stock Split?

Collegium Pharmaceutical has split 0 times.

How Many Employees Does Collegium Pharmaceutical Have?

Collegium Pharmaceutical has 357 employees.

What is the current trading status of Collegium Pharmaceutical (COLL)?

As of 18 Aug 2025, Collegium Pharmaceutical (COLL) is trading at a price of 37.74, with a previous close of 37.16. The stock has fluctuated within a day range of 37.12 to 37.85, while its 52-week range spans from 23.23 to 42.29.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.